MATTHEW RAYMOND SMITH

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Changes in body composition during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 87:599-603. 2002
  2. ncbi Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 186:2239-44. 2011
  3. ncbi Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Urol 189:S45-50. 2013
  4. ncbi Sarcopenia during androgen-deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Yawkey 7030, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 30:3271-6. 2012
  5. ncbi Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Lawrence House POB, 55 Fruit Street, Boston, MA 02114, USA
    J Gen Intern Med 24:S389-94. 2009
  6. ncbi Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
    Pierre P Major
    McMaster University, Juravinski Cancer Centre, Hamilton, Ontario, Canada
    BMC Cancer 9:272. 2009
  7. ncbi Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer
    Matthew R Smith
    Division of Hematology Oncology, Mallinckrodt General Clinical Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 71:318-22. 2008
  8. ncbi Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study
    M R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Urol 179:152-5. 2008
  9. ncbi Androgen deprivation therapy for prostate cancer: new concepts and concerns
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Endocrinol Diabetes Obes 14:247-54. 2007
  10. ncbi Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 70:315-9. 2007

Research Grants

  1. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
  2. MIDCAREER INVESTIGATOR AWARD
    Matthew Smith; Fiscal Year: 2007

Detail Information

Publications75

  1. ncbi Changes in body composition during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 87:599-603. 2002
    ..Increased fatness resulted primarily from accumulation of sc rather than intraabdominal adipose tissue...
  2. ncbi Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 186:2239-44. 2011
    ..In this post hoc analysis we evaluated the efficacy and safety of toremifene in men younger than 80 years...
  3. ncbi Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Urol 189:S45-50. 2013
    ..We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period...
  4. ncbi Sarcopenia during androgen-deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Yawkey 7030, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 30:3271-6. 2012
    ..To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT)...
  5. ncbi Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital Lawrence House POB, 55 Fruit Street, Boston, MA 02114, USA
    J Gen Intern Med 24:S389-94. 2009
    ..This population of mostly older men is medically vulnerable to a variety of treatment-associated adverse effects...
  6. ncbi Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
    Pierre P Major
    McMaster University, Juravinski Cancer Centre, Hamilton, Ontario, Canada
    BMC Cancer 9:272. 2009
    ..Because many patients with cancer die before trial completion, there is a need for survival-adjusted methods to accurately assess the effects of treatment on skeletal morbidity...
  7. ncbi Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer
    Matthew R Smith
    Division of Hematology Oncology, Mallinckrodt General Clinical Research Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 71:318-22. 2008
    ..We also assessed the relationships among changes in adipocytokines, body composition, and insulin sensitivity...
  8. ncbi Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study
    M R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Urol 179:152-5. 2008
    ..We evaluated the effects of toremifene on bone mineral density, a surrogate for fracture risk, in men receiving androgen deprivation therapy for prostate cancer...
  9. ncbi Androgen deprivation therapy for prostate cancer: new concepts and concerns
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Endocrinol Diabetes Obes 14:247-54. 2007
    ..The aim of this review is to summarize new concepts and concerns regarding treatment-related osteoporosis, diabetes, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer...
  10. ncbi Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 70:315-9. 2007
    ..Skeletal complications are a major cause of morbidity in men with hormone-refractory metastatic prostate cancer. These analyses were designed to identify the variables associated with a greater risk of skeletal complications...
  11. ncbi Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer
    Matthew R Smith
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:241-5. 2007
    ..To evaluate effects of obesity on sex steroid levels during treatment with a gonadotropin-releasing hormone agonist in men with prostate cancer...
  12. ncbi Treatment-related osteoporosis in men with prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:6315s-6319s. 2006
    ....
  13. ncbi Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Massachusetts General Hospital, Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2723-8. 2006
    ..To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in prostate-specific antigen (PSA) doubling time (PSADT) as the primary outcome variable...
  14. ncbi Markers of bone metabolism in prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Treat Rev 32:23-6. 2006
    ..Additional studies are needed to assess the potential role of bone markers in identifying men at highest risk for development of bone metastases...
  15. ncbi Therapy Insight: osteoporosis during hormone therapy for prostate cancer
    Matthew R Smith
    Harvard Medical School, Boston, MA, USA
    Nat Clin Pract Urol 2:608-15; quiz 628. 2005
    ....
  16. ncbi Insulin sensitivity during combined androgen blockade for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA
    J Clin Endocrinol Metab 91:1305-8. 2006
    ..GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity...
  17. ncbi Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer
    Matthew R Smith
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    J Urol 175:136-9; discussion 139. 2006
    ..We assessed the relationship between GnRH agonists and the risk of clinical fractures in men with prostate cancer...
  18. ncbi Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 112:2188-94. 2008
    ..To the authors' knowledge, however, less is known regarding the effects of GnRH agonists on other attributes of the metabolic syndrome...
  19. ncbi Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Yawkey 7038, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 26:1824-9. 2008
    ..We evaluated the effects of toremifene, a selective estrogen-receptor modulator, on fasting serum lipid levels in men receiving ADT for prostate cancer...
  20. ncbi Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Lancet 379:39-46. 2012
    ..We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer...
  21. ncbi Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix
    Matthew R Smith
    Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 186:1835-42. 2011
    ....
  22. ncbi Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Genitourinary Oncology Program, Boston, MA, USA
    J Bone Miner Res 26:2827-33. 2011
    ..Suppression of bone turnover markers was consistent with marked increases in bone mineral density reported previously...
  23. ncbi Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts
    Cancer 117:2077-85. 2011
    ..The natural history of castration-resistant nonmetastatic prostate cancer is poorly defined...
  24. ncbi Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 184:1316-21. 2010
    ..We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period...
  25. ncbi Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 182:2670-5. 2009
    ..We conducted subgroup analyses to evaluate the relationships between subject characteristics and the effects of denosumab on bone mineral density at multiple skeletal sites...
  26. ncbi Denosumab in men receiving androgen-deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 361:745-55. 2009
    ....
  27. ncbi Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02
    Matthew R Smith
    Department of Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 26:4333-9. 2008
    ..Diabetes is associated with lower risk of prostate cancer. Most men with diabetes are obese, and obesity is associated with greater prostate cancer mortality. Whether diabetes influences outcomes after prostate cancer diagnosis is unknown...
  28. ncbi Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Yawkey Center 7038, 55 Fruit Street, Boston, MA 02114, USA
    Curr Urol Rep 9:197-202. 2008
    ..This article describes the evidence that GnRH agonists increase risk for diabetes and cardiovascular disease and reviews the potential mechanisms for treatment-related morbidity...
  29. ncbi Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond
    Matthew R Smith
    Massachusetts General Hospital, Boston, MA 02114, USA
    Urol Oncol 26:420-5. 2008
    ..Three ongoing pivotal studies involving more than 4,500 subjects will evaluate the role of denosumab for prevention of treatment-related fractures, bone metastases, and disease-related skeletal complications in men with prostate cancer...
  30. ncbi Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?
    Matthew R Smith
    Hematology Oncology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    BJU Int 101:1335-6. 2008
  31. ncbi Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, 02114, USA
    J Clin Oncol 23:7897-903. 2005
    ..We conducted a claims-based cohort study to characterize the relationship between GnRH agonists and risk for clinical fractures in men with nonmetastatic prostate cancer...
  32. ncbi Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Division of Hematology and Oncology, Boston, 02114, USA
    Cancer Treat Rev 31:19-25. 2005
    ..Zoledronic acid is more effective than pamidronate in breast cancer and the only bisphosphonate proven effective for metastatic prostate cancer, lung cancer, renal cell carcinoma and other solid tumours...
  33. ncbi Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 101:1569-74. 2004
    ....
  34. ncbi The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy
    Matthew R Smith
    Harvard Medical School, Boston, Massachusetts, USA
    Oncology (Williston Park) 18:21-5. 2004
    ....
  35. ncbi Osteoporosis during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 60:79-85; discussion 86. 2002
    ..Other bisphosphonates are probably effective, although they have not been evaluated in this clinical setting. Alternative forms of hormonal therapy, including bicalutamide monotherapy, may cause less bone loss than ADT...
  36. ncbi Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer
    Matthew R Smith
    Division of Hematology and Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Nutrition 18:574-7. 2002
    ....
  37. ncbi Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Metastasis Rev 21:159-66. 2002
    ..Androgen deprivation therapy increases fat mass and decreases muscle mass. These body composition changes may contribute to treatment-related decreases in physical capacity and quality of life...
  38. ncbi Changes in body composition during hormonal therapy for prostate cancer
    Matthew R Smith
    Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Prostate Cancer 2:18-21. 2003
    ..Potential strategies to treat or prevent these adverse body composition changes include exercise training, alternative forms of hormonal therapy, and insulin-sensitizing agents...
  39. ncbi Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer
    Matthew R Smith
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, USA
    J Urol 170:S55-7; discussion S57-8. 2003
    ..The literature on clinical trials of bisphosphonates in men with metastatic prostate cancer is reviewed to familiarize the reader with biology of bone metastases and rationale for use of bisphosphonates...
  40. ncbi Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston 02114, USA
    Invest New Drugs 20:195-200. 2002
    ..Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer...
  41. ncbi Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma
    Matthew R Smith
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 97:789-95. 2003
    ..Treatment with estrogens or selective estrogen receptor modulators may also be effective. Monotherapy with bicalutamide or other antiandrogens may cause less bone loss than androgen deprivation therapy...
  42. ncbi Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition
    Matthew R Smith
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 22:2546-53. 2004
    ..Less is known about the effects of bicalutamide monotherapy on bone mineral density and body composition...
  43. ncbi Selective aromatase inhibition for patients with androgen-independent prostate carcinoma
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 95:1864-8. 2002
    ..The authors conducted a Phase II clinical study of letrozole to determine the safety and efficacy of a potent and selective third-generation aromatase inhibitor in men with androgen-independent prostate carcinoma...
  44. ncbi Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study
    M R Smith
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 89:1824-8. 2000
    ..The aim of this study was to determine the safety and activity of vinorelbine in combination with estramustine in men with androgen-independent metastatic prostate cancer...
  45. ncbi Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:2918-25. 2005
    ..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
  46. ncbi Low bone mineral density in hormone-naïve men with prostate carcinoma
    M R Smith
    Hematology Oncology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 91:2238-45. 2001
    ..The objective of this study was to determine the prevalence of low bone mineral density in men with prostate carcinoma and no history of androgen-deprivation therapy...
  47. ncbi Osteoporosis and obesity in men receiving hormone therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 172:S52-6; discussion S56-7. 2004
    ..A presentation on osteoporosis, obesity and obesity related disease at the Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment is summarized...
  48. ncbi Management of treatment-related osteoporosis in men with prostate cancer
    Matthew R Smith
    Haematology Oncology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Treat Rev 29:211-8. 2003
    ..Bicalutamide (150 mg daily) monotherapy increases serum ooestrogen levels and maintains bone mineral density...
  49. ncbi Osteoclast-targeted therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, MA 02114, USA
    Curr Treat Options Oncol 5:367-75. 2004
    ....
  50. ncbi Complementary and alternative therapies for advanced prostate cancer
    M R Smith
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
    Hematol Oncol Clin North Am 15:559-71. 2001
    ..Three areas are addressed: alternative forms of hormonal therapy, management of side effects of hormonal therapy, and management of skeletal complications...
  51. ncbi Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial
    Matthew R Smith
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 89:3841-6. 2004
    ..06) and trochanter (P < 0.001). In men receiving a GnRH agonist, raloxifene significantly increases bone mineral density of the hip and tends to increase bone mineral density of the spine...
  52. ncbi Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
    M R Smith
    Massachusetts General Hospital, Boston 02114, USA
    N Engl J Med 345:948-55. 2001
    ..We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist...
  53. ncbi Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 62:99-104. 2003
    ..Furthermore, castration induces secondary responses that may be of shorter duration than if started initially, although the overall period of hormonally responsive prostate cancer is more than 4 years...
  54. ncbi Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer
    Matthew R Smith
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Urology 61:127-31. 2003
    ..These observations suggest that bicalutamide monotherapy may maintain bone mineral density and prevent fractures...
  55. ncbi Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer
    M Dror Michaelson
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 107:530-5. 2006
    ..Atrasentan is an investigational agent that inhibits endothelin-1 receptor, resulting in decreased osteoblast activity...
  56. ncbi Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy
    William F Pirl
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Psychooncology 17:148-53. 2008
    ..We prospectively examined the development of depressive symptoms and fatigue among men with locally advanced prostate cancer receiving hormone therapy...
  57. ncbi Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer
    Matthew R Smith
    Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Urology 63:742-5. 2004
    ..7%, and the percentage lean mass decreased by 3.8% +/- 0.6% (P <0.001 for each comparison). CONCLUSIONS: Androgen deprivation therapy increased weight and fat mass and decreased lean mass in men with nonmetastatic prostate cancer...
  58. ncbi Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Urol 169:2008-12. 2003
    ..Zoledronic acid was well tolerated. CONCLUSIONS: Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer...
  59. ncbi Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
    M Dror Michaelson
    Division of Hematology and Oncology and Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 25:1038-42. 2007
    ..Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known...
  60. ncbi Metabolic complications of androgen deprivation therapy for prostate cancer
    Philip J Saylor
    Department of Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Urol 181:1998-2006; discussion 2007-8. 2009
    ....
  61. ncbi Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
    Daniel C Danila
    Department of Medicine, Joan and Sanford E Weill College of Medicine of Cornell University, Ithaca, NY, USA
    J Clin Oncol 28:1496-501. 2010
    ..This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy...
  62. ncbi Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
    Jason E Faris
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Curr Opin Endocrinol Diabetes Obes 17:240-6. 2010
    ..To summarize the metabolic alterations associated with androgen deprivation therapy (ADT) for prostate cancer and to evaluate the evidence linking ADT with an increased risk of diabetes and cardiovascular disease...
  63. ncbi Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer
    Philip J Saylor
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Natl Compr Canc Netw 8:211-23. 2010
    ..Currently the authors advocate the use of adapted practice guidelines developed to prevent diabetes, fractures, and coronary heart disease in the general population...
  64. ncbi Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 102:39-46. 2010
    ..We evaluated the relationship between androgen deprivation therapy and incident diabetes and cardiovascular disease in men of all ages with prostate cancer...
  65. ncbi A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts 02115, USA
    Clin Cancer Res 11:284-9. 2005
    ..To define the maximal tolerated dose, safety, and efficacy of docetaxel, carboplatin, and estramustine in patients with hormone-refractory prostate cancer (HRPC)...
  66. ncbi Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, USA
    J Clin Oncol 24:4448-56. 2006
    ..We assessed whether androgen deprivation therapy is associated with an increased incidence of diabetes and cardiovascular disease...
  67. ncbi Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31
    Jason A Efstathiou
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 110:2691-9. 2007
    ..Whether BMI is associated with prostate cancer-specific mortality (PCSM) was investigated in a large randomized trial of men treated with RT and androgen deprivation therapy (ADT) for locally advanced prostate cancer...
  68. ncbi Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 10:2705-8. 2004
    ..Little is known about the relative contributions of ADT and skeletal metastases to elevated bone turnover in men with prostate cancer...
  69. ncbi Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 22:3705-12. 2004
    ..However, the synthetic estrogens, DES and ethinyl estradiol, were detected in various lots of PC-SPES, including those used in this trial. Clinical trials that utilize herbal therapies must account for issues of purity and consistency...
  70. ncbi Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Hematology Oncology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Drugs Aging 20:175-83. 2003
    ..Additional prospective studies are needed to evaluate the long-term effects of bisphosphonates on fracture risk and disease-related outcomes...
  71. ncbi Use of androgen deprivation therapy for metastatic prostate cancer in older men
    Nancy L Keating
    Division of General Internal Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1077-83. 2008
    ....
  72. ncbi Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Urol 184:2313-9. 2010
    ..We assessed the cardiovascular safety profile of degarelix, a new gonadotropin-releasing hormone antagonist...
  73. ncbi Bisphosphonates for treatment and prevention of bone metastases
    M Dror Michaelson
    Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 23:8219-24. 2005
    ....
  74. ncbi Novel bone-targeted strategies in oncology
    Sonia Vallet
    Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Clin Cancer Res 16:4084-93. 2010
    ....
  75. ncbi Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma
    Hang Lee
    Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 104:1633-7. 2005
    ..CONCLUSIONS: The results of the current study showed that fat mass increased and lean body mass decreased mostly during initial GnRH agonist therapy whereas BMD decreased steadily during initial and long-term treatment...

Research Grants3

  1. ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Matthew Smith; Fiscal Year: 2004
    ..In addition, this project will provide important insights into the relative contributions of testosterone and estrogen in bone metabolism, and maintenance of muscle size and strength in older men. ..
  2. MIDCAREER INVESTIGATOR AWARD
    Matthew Smith; Fiscal Year: 2007
    ..In addition, this research program may help decrease the burden of cancer treatment for prostate cancer survivors. ..